Document is current
Any future updates will be listed below
-
Authors
Hendrianus, Hendrianus
Jeong, Young-Hoon
Lee, Sang Yeub
Cho, Jun Hwan
Jo, Jinhwan
Gorog, Diana A.
Kubica, Jacek
Tantry, Udaya S.
Gurbel, Paul A.
Kim, Sang-Wook
-
Funding
Funding for this research was provided by:
Science Research Program funded by Sinai Center for Thrombosis Research (SCTR) and Drug Development
- License Information
-
More Information
Article History
Received: 27 October 2025
Accepted: 19 December 2025
First Online: 28 December 2025
Declarations
:
: Not applicable.
: Not applicable.
: YHJ has received honoraria for lectures from Daiichi Sankyo, Sanofi-Aventis, Han-mi Pharmaceuticals, and Daewoong Pharmaceuticals and research grants or support from Samjin Pharmaceuticals, Hanmi Pharmaceuticals, Yuhan Pharmaceuticals, Biotronik Korea, and U and I Corporation. DAG reports institutional grants from AstraZeneca, and honoraria from BMS, Janssen and Chiesi. JK has been involved in the DAPT-SHOCK-AMI trial as an investigator and received personal fees from AstraZeneca, Ferrer, Adamed and Krka. PAG has received grants and personal fees from Bayer HealthCare, Otitopic, Amgen, and Janssen, US World-Meds; grants from Instrumentation Laboratory, Hikari Dx, Haemonetics, Medicure, and Idorsia Pharmaceuticals; and personal fees from UpToDate and has patents “Detection of Restenosis Risk in Patients Issued” and “Assessment of Cardiac Health and Thrombotic Risk in a Patient.”
